Highlights:
 Effective stroke prevention in atrial fibrillation requires oral anticoagulation.
 Globally, similar proportions of women and men were prescribed oral anticoagulation.
 The decision to prescribe oral anticoagulation does not seem to be genderdependant.
 Other non-gender risk factors play a predominant role in anticoagulation decision making.
Abstract

Aims
Data on gender differences in oral anticoagulation for stroke prevention in patients with atrial fibrillation are conflicting, largely limited to regional reports and Vitamin K antagonist (VKA) use. We aimed to analyze gender-specific anticoagulant prescription patterns early following the introduction of non-VKA oral anticoagulants (NOACs) in a large, global registry on atrial fibrillation.
Methods and Results
Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) is an international registry program involving patients with newly diagnosed atrial fibrillation (<3 months from arrhythmia onset). We used data from 15,092 consecutive patients (median age 71.0 years; women 45.5%) enrolled between 2011 and 2014. Globally, 79.7% women and 80.2% men were anticoagulated; the absolute betweengender difference in prevalence of anticoagulant use was −0.5% (95% CI, −1.8%, 0.8%). VKAs
Introduction
Atrial fibrillation increases the risk of stroke. 1, 2 For reasons not entirely clear, thromboembolic risk is overall higher in women than in men. [3] [4] [5] Gender-specific arterial structure, alternations in blood flow and endothelial function, increased inflammatory and thrombogenic status are examples of the potential reasons for this difference. 6, 7 Consequently, female gender has been incorporated into the stroke risk stratification scheme, i.e., CHA 2 DS 2 -VASc (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke/transient ischemic attack [TIA] , vascular disease, age 65-74 years, sex category [female]). 8 The majority of guidelines for atrial fibrillation recommend that oral anticoagulation should be considered in patients with ≥1 non-gender related risk factors for stroke (i.e., CHA 2 DS 2 -VASc ≥1 in men and CHA 2 DS 2 -VASc ≥2 in women). [9] [10] [11] [12] [13] Despite these recommendations, published data indicate variability in anticoagulation by gender, ranging from a 50% lower uptake in women versus men to more prevalent anticoagulation in women. 6, [14] [15] [16] [17] Patients described in these reports were geographically clustered and the anticoagulant was largely confined to Vitamin K antagonists (VKAs). Here we present findings from Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF), which provides a unique opportunity to assess contemporary anticoagulation uptake worldwide. 18 The Phase II data allow for analyses of early practice patterns following the introduction of non-VKA oral anticoagulants (NOACs).
Our goal was to assess baseline antithrombotic treatment strategies in women versus men and identify potential gender-related gaps in treatment for stroke prevention.
Methods
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Study Design
The design of GLORIA-AF has been published. 18 In short, GLORIA-AF is a large ongoing, prospective registry program enrolling patients with a diagnosis of new onset, non-valvular atrial fibrillation at risk for stroke. Inclusion criteria are: adult, newly diagnosed non-valvular atrial fibrillation (<3 months prior study enrolment), and ≥1 stroke risk factor in the CHA 2 DS 2 VASc scale. The main exclusion criteria are mechanical heart valve or valvular disease with the need for surgical intervention, prior VKA therapy for any reason for >60 days, indications other than atrial fibrillation for anticoagulant use, reversible cause of arrhythmia and life expectancy <1 year.
Thromboembolic and bleeding risks were assessed based on CHA 2 DS 2 -VASc and HAS-BLED (hypertension, abnormal renal and liver function, stroke, bleeding, age ≥65 years, drugs or alcohol) scales, respectively. 8, 19 Low-risk of stroke was defined by CHA 2 DS 2 -VASc=1 in women (men with CHA 2 DS 2 -VASc=0 were not recruited); moderate-risk were men with CHA 2 DS 2 -VASc=1; and high-risk were those with CHA 2 DS 2 -VASc score ≥2, irrespective of gender. Bleeding risk was defined as low (HAS-BLED score<3) or high (score≥3). 19 
Data Collection and Timelines
For collection, storing and assuring safety and confidentiality of data, a validated Electronic Data Capture System was employed. To monitor data quality, multiple edit checks, data quality reviews and on-site monitoring visits were arranged and local investigators were instructed on system functionality and requirements. This analysis is based on crosssectional, baseline data of patients enrolled from 2011 through 2014 (Phase II of the program, after first NOACs availability).
Statistical Analysis
The continuous variables were expressed as median (Q1, Q3), whereas categorical variables as frequencies and percentages. To investigate the absolute between-gender difference in anticoagulation prescription, both overall and within strata defined by covariates, a binomial regression analysis was employed. 20 Binomial regression allows direct estimation of the difference between proportions of males and females prescribed anticoagulants. The first step of the analysis was to screen out potential confounders for gender. The change−in−estimate method was applied to verify how much adjusting one covariate can change the coefficient (anticoagulant prescription difference) of gender using binomial regression. To be considered potential confounders requiring adjustment in subsequent multivariable analyses, covariates were required to change the gender coefficient by at least 10%.
The second step was to investigate the overall gender difference in anticoagulant prescription by multivariable binomial regression analysis including gender and all potential confounders found, if any, in the first step. The third step was to investigate the gender differences within strata defined by covariates of clinical relevance, as outlined in Table S2 .
The multivariable binomial regression analyses were performed, each with 2 risk factors (gender and another risk factor) and the interaction term, along with all potential confounders found, if any, in the first step, associated with prescription of anticoagulation against no anticoagulation.
Confidence intervals were based on likelihood ratio. Patients with missing values were excluded from the binomial regression analyses. Analyses were performed using SAS statistical software version 9.4 (SAS Institute, Inc., Cary, NC, USA).
Results
Overall, 15,092 consecutive patients (45.5% women) were enrolled ( Table 1) . Women were older, with 45.8% ≥75 years, compared with 33.6% men. The prevalences of hypertension, hyperlipidemia, diabetes, previous stroke/TIA, abnormal kidney function, previous bleeding episode and cancer were similar in both genders. A quarter of men (24.8%) had coronary artery disease and 13.8% prior myocardial infarction, whereas for women the corresponding proportions were approximately 50% lower. Paroxysmal atrial fibrillation was more common in women (57.2%) than in men (50.1%), as was symptomatic arrhythmia (31.4% versus 25.5%, respectively).
Based on the CHA 2 DS 2 -VASc score, low risk of stroke was observed in 4.8% of women (score=1; female with no additional stroke risk factors), and 95.2% were at high risk (score ≥2). Moderate risk of stroke (score=1) was observed in 21.4% of men and high risk (score ≥2) in 78.6% men ( Table 2 ). Bleeding risk was unknown for 10.3% of women (men: 13.2%), low for 81.3% of women (men: 77.1%) and high for 8.4% of women (men: 9.7%), as assessed by the HAS-BLED score.
Confounders For Gender in the Oral Anticoagulation Prescription
By the change−in−estimate method, because all covariates caused relatively small changes (less than 10%) for the coefficient of gender in the binomial regression, no covariate was identified as a potential confounder that needed adjustment in subsequent analyses (Table   S1 ).
Antithrombotic Therapy in Women and Men
Overall, 79.7% of women and 80.2% men were prescribed anticoagulants (Table 2) , the absolute between-gender difference (women versus men) in anticoagulant use being −0.5% (95% CI, −1.8%, 0.8%) [ Table S1 ]. Anticoagulant choice was similar between genders: 32.8% women and 31.9% men were prescribed VKAs (NOACs 46.8 % and 48.3%). Overall, 8.1% of women and 7.6% men were given no antithrombotic therapy, while aspirin was prescribed to 11.3% of both genders.
Antithrombotic Therapy in Relation to Stroke and Bleeding Risks
Antithrombotic therapies in relation to thromboembolic risk are presented in Figure 1 , Panel A. For CHA 2 DS 2 -VASc=1, 46.1% of women and 69.8% of men were prescribed anticoagulants, whereas the corresponding proportions for CHA 2 DS 2 -VASc score ≥2 were 81.4% and 83.0%, respectively. Detailed treatment strategies according to stroke risk (as per CHA 2 DS 2 -VASc score 1-9) are presented in Figure 2 , separately for women (Panel A) and men (Panel B).
Of the studied population, 18.3% of women and 17.0% men at low risk of bleeding (HAS-BLED score of 0-2) were not anticoagulated, whereas the corresponding proportions for those at high risk of hemorrhage (HAS-BLED ≥3) were 34.7% and 31.6%, respectively ( Figure   1 , Panel B). Aspirin was the most commonly prescribed antithrombotic drug in both women (28.3%) and men (27.1%) at high risk of bleeding.
Antithrombotic Treatment by Geographic Region
Apart from evident between-region differences in overall anticoagulant use and choice of specific anticoagulant agents, oral anticoagulation by gender was similar within particular regions ( Figure 3 ). The exception was noted in North America, where fewer women (75.9%) than men (80.4%) were anticoagulated. The corresponding proportions for anticoagulant use by females and males in other regions were as follows: 54.4 vs 55.8% in Asia; 89.9 vs 90.2% in Europe, 86.8 vs 84.1% in Latin America and 88.7 vs 86.3% for Africa/Middle East, respectively.
Gender Difference in Anticoagulation Prescription by Covariates
Gender differences in oral anticoagulant prescription within strata defined by variables of clinical relevance and their interaction term associated with prescription of anticoagulation against no anticoagulation are presented in Figure 1 , Panel C and Table S2 . Between-gender (women versus men) differences in anticoagulant use were found for (by decreasing order of magnitude of the difference): CHA 2 DS 2 -VASc score=1; CHADS 2 score=0; previous bleeding; age <65 years; no history of hypertension; myocardial infarction; coronary artery disease; North America region; and specialist office setting.
Discussion
The principal finding of our study is that globally similar proportions of women (79.7%) and men (80.2%) are prescribed oral anticoagulation for stroke prevention in atrial fibrillation.
Second, oral anticoagulant choice is unaffected by gender (approximately 1/3 and 1/2 are prescribed VKAs and NOACs, respectively). Third, when exploring subgroups, the most important difference in anticoagulant use identified between women and men is for patients with a CHA 2 DS 2 -VASc score of 1 (46.1% of women and 69.8% of men, respectively); this difference may be linked to guideline recommendations for atrial fibrillation, hence the decision to prescribe anticoagulation is not gender-dependent, but may rely predominately upon clinical stroke risk factors.
Although we found no confounders for the association between gender and anticoagulant use as well as global anticoagulation was nearly identical amongst women and men, we identified several factors of clinical relevance to interact with gender and anticoagulants prescription (i.e., thromboembolic risk, previous bleeding, age, geographic region, health care setting, comorbid coronary artery disease, myocardial infarction or hypertension).
The largest between-gender difference in anticoagulant use (46.1% and 69.8% for women and men, respectively) was found for CHA 2 DS 2 -VASc score of 1. This reflects a different clinical approach to a score of 1 in both genders, rather than an underuse of anticoagulation in women compared with men. On the contrary, women with this score seem over-treated with anticoagulants. Indeed, past European guidelines (in effect during enrolment period for Phase II of GLORIA-AF, 2011-2014) as well as present guidelines in Europe state that women with CHA 2 DS 2 -VASc=1 (1 point for female gender only) are at "truly low-risk" for stroke and should not be anticoagulated as this brings no benefit but may cause harm. [9] [10] [11] By contrast, anticoagulation should be considered in patients with 1 non-gender related risk factors for stroke, that is CHA 2 DS 2 -VASc=1 for men and CHA 2 DS 2 -VASc=2 for women. 9, 10 We observed similar proportions of women and men with one non-gender related risk factor being anticoagulated (71.9% and 69.1%, respectively).
A similar pattern (less anticoagulant use for women than men) was noted for those aged <65 years with no history of hypertension, which seems to reflect treatment strategy for low risk patients. We observed no between-gender differences for patients ≥65 years of age or with comorbid hypertension. Indeed, on the other side of the stroke risk continuum (highrisk cohort), as defined by the CHA 2 DS 2 -VASc ≥2 (regardless of gender), we observed a similar anticoagulation by women and men, at 81.4% and 83.0%, respectively. Nonetheless, we found that fewer women than men were anticoagulated if they had a previous bleeding event, even though no major between-gender differences were noted with regard to bleeding risk, as per HAS-BLED scheme. The reasons for this disparity in anticoagulation patterns between men and women are not fully understood, but perhaps may reflect a differently perceived (higher in women) risk of bleeding complications in relation to gender. Importantly, the net clinical benefit of anticoagulation, when balancing stroke risk reduction versus increased risk of bleeding, is positive and even greater in patients at increased risk of bleeding. 21, 22 Regional disparities in anticoagulant use by gender may result from various guideline recommendations issued by different societies, largely due to different thresholds for anticoagulation initiation. 23, 24 We found that fewer women than men were anticoagulated in North America. Our findings are consistent with recent report of the PINNACLE Registry, which found that in North America women are less likely to be anticoagulated. 25 Unlike European guidelines, the American recommendations offer OAC, aspirin or no stroke prophylaxis to patients with CHA 2 DS 2 -VASc=1 (regardless of gender), whereas anticoagulation is recommended for those with the score ≥2. 11, 26 By considering female gender as a risk factor for those with CHA 2 DS 2 -VASc=1, the American guidelines (in contrast to European guidelines) could potentially be recommending anticoagulation for women who may be at truly low risk for stroke (thus, potential drug overuse), whereas anticoagulants may be underused in men at moderate risk of stroke. 24, 27, 28 Although the difference in anticoagulation rates amongst women versus men in North America is modest, patients with one risk factor for stroke constitute only the minority of atrial fibrillation population, for example only 13.9% in the present analysis (and taking into account the fact that men with CHA 2 DS 2 -VASc=0 were not recruited by GLORIA-AF). Importantly, though 1-year stroke rates in untreated patients with only 1 risk factor for stroke (beyond gender) vary amongst studies, the majority of reports show evident clinical benefit of anticoagulation versus no anticoagulation. 24, [27] [28] [29] [30] The same reports show also no benefit of anticoagulation in patients with no stroke risk factors, that is men with CHA 2 DS 2 -VASc=0 and women with CHA 2 DS 2 -VASc=1 (one point for female gender only).
In Canada, female gender is not perceived as a stroke risk factor and anticoagulation is recommended for patients with CHADS 2 ≥1 (Congestive Heart Failure, Hypertension, Age≥75, Diabetes, Stroke/TIA). 31 We observed no difference in anticoagulant use by gender for CHADS 2 ≥1, but fewer women than men were anticoagulated if CHADS 2 score was 0. In contrast to CHA 2 DS 2 -VASc scoring system, employment of CHADS 2 scheme may underestimate the risk of stroke in patients categorized as low risk (score=0). 32 Indeed, in Canada, a woman age <65 years with vascular disease is not recommended anticoagulation (CHADS 2 =0), whereas in Europe anticoagulation is considered/indicated (CHA 2 DS 2 -VASc=2) for such women. [9] [10] [11] [12] Importantly, women versus men with vascular disease (i.e. coronary artery disease and prior myocardial infarction) in the present analysis were less likely to be anticoagulated.
A recent report from 3 nationwide registries suggests that female gender is a "stroke risk modifier" rather than a "stroke risk factor" and although stroke risk may be higher in women versus men it seems that "female gender" may be safely omitted in decision making on oral anticoagulation prescription. 33 Thus, use of a CHA 2 DS 2 -VA score (i.e. excluding gender criterion) may be considered.
Limitations
Per study protocol, GLORIA-AF recruited patients with CHA 2 DS 2 -VASc score ≥1. Thus, no data on males with score zero (low-risk of stroke) were available. Our analyses are based on the prescription of baseline anticoagulation in relation to gender, and thus we could assess neither quality of anticoagulation nor changes in practice patterns over time. Only patients with new onset atrial fibrillation (not all-comers) were recruited. Both patients and physicians knew they were participants of a registry program and patients could join the study only after signing an informed consent. This might have led to higher overall anticoagulation rates compared with general population.
In order to analyze many clinically important factors affecting decision making on anticoagulation prescription, we have performed a log-binomial analysis of anticoagulant use against no anticoagulant use, instead of analyzing the use of each of the anticoagulants separately. Also, we did not analyze the associations between anticoagulant use and concomitant dual antiplatelet therapy use by gender. A detailed analysis of various combinations of antiplatelet therapy use ± anticoagulant use that may have varying durations of use is beyond the scope of the current analysis that focuses on gender differences.
We used a 10% absolute change in the coefficient of gender as a cut-off for identification of confounders of the association between gender and anticoagulant use. More typically, a 10% relative change is used. We opted for an absolute cut-off because the effect of gender on anticoagulant use seems nearly null. The results would have been unchanged for any absolute change threshold above 2.3% (Table S1 ). With the threshold 2.3% (or any above 1.1%), the retained model would have adjusted for CHA 2 DS 2 −VASc score and the resulting absolute difference in anticoagulation between women and men would have shifted from -0.5% (95% CI −1.8, 0.8) to -2.8% (−4.0,−1.5) (Table S1 ), which would still support our principal finding that the oral anticoagulant use is globally similar between women and men.
In addition, a model estimating the effect of gender when adjusting for all other factors has been reported; 34 the effect of gender on anticoagulation was not affected by the adjustments (relative risk of anticoagulant prescription for females compared with males: 0.99 unadjusted vs. 0.99 adjusted for all other factors). We have therefore no reason to suspect that our results were sensitive to this choice.
A few variables had non-negligible proportions of missing values. For example, creatinine clearance had 21% missing, HAS-BLED score had 12% missing, and alcohol abuse had 8% missing. Multiple imputation to deal with missing values was not planned in the phase II analyses, which are mostly descriptive, but this will be considered for phase III.
Conclusion
Globally, the prevalence of anticoagulant use is similar in women and men. The decision to prescribe oral anticoagulation seems to depend predominantly upon guideline-related differences in stroke risk stratification rather than on gender. Overall oral anticoagulation 12065 (79.9) 5474 (79.7) 6591 (80.2) ASA = aspirin; NOAC = non-Vitamin K antagonist oral anticoagulants; VKA = Vitamin K antagonists; Other = antiplatelets other than aspirin and combination of anticoagulant agents; SD = standard deviation Unknown/missing values: 2 for CHADS 2 score class, 1786 for HAS-BLED risk score class. 
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